Overexpression of LncRNA H19/miR-675 Promotes Tumorigenesis in Head and Neck Squamous Cell Carcinoma

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2016 Dec 21

PMID 27994496

Citations 42

Authors

Guo-Fang Guan

De-Jun Zhang

Lian-Ji Wen

Ding Xin

Yan Liu

Duo-Jiao Yu

Kai Su

Lin Zhu

Ying-Yuan Guo

Ke Wang

Affiliations

Soon will be listed here.

Abstract

There is accumulating evidence indicating that long non-coding RNA H19 and its mature product miR-675 play essential roles for tumor growth and progression. However, their prognostic value in human head and neck squamous cell carcinoma (HNSCC), particular in laryngeal carcinoma, remains to be elucidated. In this study, we observed that both H19 and miR-675 were significantly overexpressed in a cohort of 65 primary tumor samples and two HNSCC cell lines. Importantly, when paired with patient follow-up data, higher expression of either H19 or miR-675 was significantly correlated with higher risk of patient relapse, and associated with worse overall survival and poor disease-free survival. Knockdown miR-675 caused significant reduction of cell viability, migratory and invasive capabilities. Taken together, these results suggest that the strong correlation of H19 overexpression together with higher miR-675 and lymph node metastases could be useful predictive markers, indicating a potentially therapeutic strategy for HNSCC patients.

Citing Articles

Influence of H19 polymorphisms on breast cancer: risk assessment and prognostic implications via LincRNA H19/miR-675 and downstream pathways.

Qi Y, Zhao P Front Oncol. 2024; 14:1436874.

PMID: 39267845 PMC: 11390531. DOI: 10.3389/fonc.2024.1436874.

Epigenetic modulation of long noncoding RNA H19 in oral squamous cell carcinoma-A narrative review.

Rajendran P, Sekar R, Abdallah B, Jh S, Ali E, Jayaraman S Noncoding RNA Res. 2024; 9(2):602-611.

PMID: 38532798 PMC: 10963247. DOI: 10.1016/j.ncrna.2024.01.020.

Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.

Jayawickrama S, Ranaweera P, Pradeep R, Jayasinghe Y, Senevirathna K, Hilmi A Cancer Rep (Hoboken). 2024; 7(3):e2045.

PMID: 38522008 PMC: 10961052. DOI: 10.1002/cnr2.2045.

The Potential microRNA Prognostic Signature in HNSCCs: A Systematic Review.

Dioguardi M, Spirito F, Iacovelli G, Sovereto D, Laneve E, Laino L Noncoding RNA. 2023; 9(5).

PMID: 37736900 PMC: 10514860. DOI: 10.3390/ncrna9050054.

Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.

Jayaraj R, Polpaya K, Kunale M, Kodiveri Muthukaliannan G, Shetty S, Baxi S Genes (Basel). 2022; 13(12).

PMID: 36553594 PMC: 9777665. DOI: 10.3390/genes13122325.

References

Mattick J . Long noncoding RNAs in cell and developmental biology. Semin Cell Dev Biol. 2011; 22(4):327. DOI: 10.1016/j.semcdb.2011.05.002. View

Liang W, Fu W, Wong C, Wang Y, Wang W, Hu G . The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015; 6(26):22513-25. PMC: 4673179. DOI: 10.18632/oncotarget.4154. View

Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P . H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015; 6(30):29209-23. PMC: 4745721. DOI: 10.18632/oncotarget.4976. View

Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T . H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol. 2005; 58(10):1064-8. PMC: 1770739. DOI: 10.1136/jcp.2004.023648. View

Zou T, Jaladanki S, Liu L, Xiao L, Chung H, Wang J . H19 Long Noncoding RNA Regulates Intestinal Epithelial Barrier Function via MicroRNA 675 by Interacting with RNA-Binding Protein HuR. Mol Cell Biol. 2016; 36(9):1332-41. PMC: 4836219. DOI: 10.1128/MCB.01030-15. View

Matouk I, Raveh E, Abu-Lail R, Mezan S, Gilon M, Gershtain E . Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys Acta. 2014; 1843(7):1414-26. DOI: 10.1016/j.bbamcr.2014.03.023. View

Matouk I, Halle D, Gilon M, Hochberg A . The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer. J Transl Med. 2015; 13:113. PMC: 4397711. DOI: 10.1186/s12967-015-0467-3. View

Ribarska T, Goering W, Droop J, Bastian K, Ingenwerth M, Schulz W . Deregulation of an imprinted gene network in prostate cancer. Epigenetics. 2014; 9(5):704-17. PMC: 4063830. DOI: 10.4161/epi.28006. View

Nakao M, Sasaki H . Genomic imprinting: significance in development and diseases and the molecular mechanisms. J Biochem. 1996; 120(3):467-73. DOI: 10.1093/oxfordjournals.jbchem.a021434. View

10.

Gao T, He B, Pan Y, Gu L, Chen L, Nie Z . H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway. Clin Transl Oncol. 2013; 16(4):410-7. DOI: 10.1007/s12094-013-1098-x. View

11.

Mele M, Ferreira P, Reverter F, DeLuca D, Monlong J, Sammeth M . Human genomics. The human transcriptome across tissues and individuals. Science. 2015; 348(6235):660-5. PMC: 4547472. DOI: 10.1126/science.aaa0355. View

12.

Xu C, Yang M, Tian J, Wang X, Li Z . MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol. 2011; 39(1):169-75. DOI: 10.3892/ijo.2011.1007. View

13.

Sorin V, Ohana P, Gallula J, Birman T, Matouk I, Hubert A . H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. ISRN Oncol. 2012; 2012:351750. PMC: 3371723. DOI: 10.5402/2012/351750. View

14.

Tsang W, Ng E, Ng S, Jin H, Yu J, Sung J . Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2009; 31(3):350-8. DOI: 10.1093/carcin/bgp181. View

15.

Byun H, Wong H, Birnstein E, Wolff E, Liang G, Yang A . Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res. 2007; 67(22):10753-8. DOI: 10.1158/0008-5472.CAN-07-0329. View

16.

Zhuang M, Gao W, Xu J, Wang P, Shu Y . The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem Biophys Res Commun. 2014; 448(3):315-22. DOI: 10.1016/j.bbrc.2013.12.126. View

17.

Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G . The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol. 2012; 14(7):659-65. PMC: 3389517. DOI: 10.1038/ncb2521. View

18.

Ariel I, De Groot N, Hochberg A . Imprinted H19 gene expression in embryogenesis and human cancer: the oncofetal connection. Am J Med Genet. 2000; 91(1):46-50. DOI: 10.1002/(sici)1096-8628(20000306)91:1<46::aid-ajmg8>3.0.co;2-i. View

19.

Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T . Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011; 71(20):6320-6. DOI: 10.1158/0008-5472.CAN-11-1021. View

20.

Schmidt L, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D . The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011; 6(12):1984-92. DOI: 10.1097/JTO.0b013e3182307eac. View